Please login to the form below

Not currently logged in
Email:
Password:

Medivir buys BioPhausia

Medivir acquires BioPhausia in €62m deal as it looks to market new hepatitis C drug

Swedish company Medivir, which develops pharmaceuticals against infectious diseases caused by viruses, is to acquire specialty pharmaceutical company BioPhausia for SEK565 million (€62m).

Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market by 2013.

Ron Long, chief executive of Medivir, said: "The task in hand for us is to put ourselves in a position where we can educate the market about the virtues and advantages of TMC435.”

Under the terms of the deal, Medivir is offering a mixture of cash and new shares.

13th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics